Gene Expression Signature for CAP Prognosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting the severity of community-acquired pneumonia (CAP) are inadequate, particularly in identifying patients who will develop a severe course of the disease upon admission.
Innovation Solution
A diagnostic method involving the analysis of whole blood transcriptome data to identify a gene expression signature that can predict the disease course of CAP upon admission, using specific nucleic acids such as CLEC4A, KLRB1, SIGLEC14, TNFSF14, and YOD1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If clinical scoring systems (CURB65, PSI, SOFA) are used for prognosis, then the assessment is simple and quick, but the predictive power for severe disease course and ICU admission is insufficient
Solution Approach 1:
The patent changes the measurement parameters from simple clinical scores to gene expression levels. By analyzing the expression levels of specific genes (e.g., IL6, TNF, IL1B, CCL2, CXCL8) in patient samples, the system achieves superior predictive power for severe CAP courses and ICU admission while maintaining a manageable assessment process through standardized molecular testing protocols.
2Measurement precision
If gene expression analysis is performed to improve prediction accuracy, then the prognostic precision is enhanced, but the ease of operation and accessibility is reduced
Solution Approach 1:
The patent replaces complex mechanical/clinical assessment procedures with molecular biology-based detection methods. By using gene expression analysis of specific biomarkers, the system achieves high prognostic precision while streamlining the operational process through standardized sample collection and molecular testing, making advanced prognosis accessible in clinical settings.
3Reliability
If molecular biomarkers are used for early risk stratification, then the ability to identify high-risk patients is improved, but the cost and technical requirements increase
Solution Approach 1:
The patent extracts and measures specific gene expression markers from patient samples to create a focused risk stratification tool. By selecting and analyzing a defined panel of genes associated with severe CAP outcomes, the system achieves reliable early risk identification while avoiding the need for comprehensive genomic sequencing or overly complex molecular assays.
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
The present invention refers to a diagnostic method for the ex-vivo prognosis, prediction or risk stratification for mortality, disease outcome or ICU admission of a patient who has been diagnosed with community acquired pneumonia (CAP) comprising the steps of i) providing a sample from the patient and ii) analysing the expression level of at least one nucleic acid in the sample, wherein the patient's prognosis, prediction or risk stratification is determined according to the expression levels of the at least one nucleic acid. The at least on nucleic acid is selected from a gene signature comprising biomarkers as identified in the present invention. In further aspects the present invention also refers to the nucleic acids of the gene signature and their use for prognosis and risk stratification. Finally, the present invention also refers to a diagnostic kit for performing the method of the invention